Browse medicines, page 3 of 6

Use listed on the medicine record

The detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests

Use listed on the medicine record

The prophylaxis and treatment of acute rejection

Use listed on the medicine record

Adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy

Use listed on the medicine record

Prurigo nodularis

Use listed on the medicine record

Skeletal imaging to demonstrate areas of altered osteogenesis

Use listed on the medicine record

Exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy

Use listed on the medicine record

Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Use listed on the medicine record

Blastic plasmacytoid dendritic cell neoplasm

Use listed on the medicine record

Wounds

Use listed on the medicine record

ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Use listed on the medicine record

Adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma

Use listed on the medicine record

Relapsed or refractory multiple myeloma

Use listed on the medicine record

Attention Deficit Hyperactivity Disorder

Use listed on the medicine record

TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1.

Use listed on the medicine record

Itching associated with signs and symptoms of allergic conjunctivitis

Use listed on the medicine record

Β-thalassemia who require regular red blood cell (RBC) transfusions

Use listed on the medicine record

Neurotrophic keratitis

Use listed on the medicine record

Hereditary Factor X deficiency

Use listed on the medicine record

DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] .

Use listed on the medicine record

Severe asthma characterized by an eosinophilic phenotype

Use listed on the medicine record

Use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors

Use listed on the medicine record

RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Use listed on the medicine record

Adenosine deaminase severe combined immune deficiency

Use listed on the medicine record

Muscle invasive bladder cancer

Use listed on the medicine record

EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Iron deficiency anemia

Use listed on the medicine record

The amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after

Use listed on the medicine record

Treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable

Use listed on the medicine record

Use with manual compression

Use listed on the medicine record

SARCLISA ESCENA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Use listed on the medicine record

Moderate-to-severe atopic dermatitis

Use listed on the medicine record

Unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive

Use listed on the medicine record

SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH). Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). SKYTROFA is a human growth hormone indicated for: Pediatric Patients: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH) ( 1 ).

Use listed on the medicine record

Relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy